Welcome to our dedicated page for Doximity SEC filings (Ticker: DOCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Doximity’s filings don’t read like a traditional tech company; every page weaves HIPAA obligations, clinician engagement metrics, and life-science ad revenue into one dense narrative. If you need the Doximity annual report 10-K simplified or want to see how tele-health adoption shifts quarter-to-quarter inside a Doximity quarterly earnings report 10-Q filing, you’re in the right place.
Stock Titan applies AI models built for regulatory language, understanding Doximity SEC documents with AI so you don’t have to. We tag risk factors, pull out user-growth charts, and alert you to Doximity insider trading Form 4 transactions within minutes of submission. Whether it’s a sudden product-launch 8-K or the annual Doximity proxy statement executive compensation, our platform delivers context alongside the raw text.
Use cases our members rely on every day:
- Instant push notifications for Doximity Form 4 insider transactions real-time and other executive stock moves.
- Side-by-side redlines that make a Doximity earnings report filing analysis a two-minute task, not an afternoon.
- One-click highlights that turn “Risk Factors” into an at-a-glance checklist, making Doximity 8-K material events explained in plain English.
From Doximity executive stock transactions Form 4 to the next Doximity SEC filings explained simply, every document flows into our real-time feed, fully searchable and linked to prior periods. Spend less time hunting through EDGAR and more time acting on clear, AI-powered insights.
Doximity (NYSE:DOCS) filed a Form 4 revealing that director Regina M. Benjamin exercised 10,000 stock options at $2.21, converted the resulting Class B shares into Class A, and immediately sold those 10,000 Class A shares at $60 on 06/25/2025. The trade was executed under a pre-arranged Rule 10b5-1 plan adopted 02/26/2025.
The gross proceeds total roughly $600,000, representing about 38% of Benjamin’s direct Class A position before the sale. After the transactions she still directly owns 16,618 Class A shares and holds 371,138 option shares.
Doximity (NYSE:DOCS) director Timothy S. Cabral filed Form 4 reporting a same-day option exercise and sale on 06/25/2025.
Cabral converted 10,000 Class B shares into Class A at a $2.21 strike, then sold the entire block at $60.00 per share under a Rule 10b5-1 plan adopted 02/13/2025, generating roughly $600,000 in gross proceeds. His direct Class A holdings fell from 16,360 to 6,360 shares, a 61% reduction. No additional acquisitions or new compensation arrangements were disclosed.
Form 144 Notice of Proposed Sale filed for Doximity (NYSE: DOCS) indicates an insider sale transaction. Timothy Cabral plans to sell 10,000 shares of common stock with an aggregate market value of $600,000, to be executed through Morgan Stanley Smith Barney LLC.
Key transaction details:
- Securities were acquired through stock option exercise on June 25, 2025
- Sale represents a small fraction of total outstanding shares (187,826,153)
- Planned execution date: June 25, 2025
- Previous sale by the same insider: 10,000 shares sold on May 23, 2025 for $505,796
This Form 144 filing represents a declaration of intent to sell securities and confirms the seller has no knowledge of undisclosed material adverse information regarding Doximity's operations.
FAQ
What is the current stock price of Doximity (DOCS)?
What is the market cap of Doximity (DOCS)?
What is the core business of Doximity Inc?
How does Doximity ensure the security and privacy of its users?
What features make Doximity stand out in the healthcare industry?
Who are the primary users of Doximity?
How does Doximity generate revenue?
How does Doximity compare to traditional professional social networks?
Is Doximity accessible on mobile devices?
What role does Doximity play in enhancing patient care?
